Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
المؤلفون المشاركون
Tamura, Kenji
Seo, Takuji
Noguchi, Emi
Yoshida, Masayuki
Mori, Taisuke
Tanioka, Maki
Sudo, Kazuki
Shimomura, Akihiko
Fujiwara, Yasuhiro
Yonemori, Kan
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-03-06
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background.
Metaplastic breast carcinomas are rare and carry poor prognoses.
They are also more aggressive than other breast cancers and are known for their resistance to chemotherapy.
Prolonged treatment with dabrafenib and trametinib is a therapy for malignant melanoma that improves the progression-free survival and overall survival.
Such molecular-targeted therapies are also being developed for cancers with BRAF mutation, a driver of malignant melanoma.
Case Presentation.
A 57-year-old woman with metaplastic breast cancer and chemotherapy-refractory massive pleural effusion.
After contained anthracycline regimen failure, her breast cancer progressed to an advanced stage.
We ordered next-generation sequencing- (NGS-) based tumor molecular profiling from core needle biopsy of the breast.
The NGS report indicated the presence of a BRAF V600E mutation.
After initiation of dabrafenib and trametinib, her symptom and the pleural effusion were decreased.
The first assessment of CT scans showed a decreased pleural effusion and shrunken subcutaneous lesions.
Approximately 2 weeks later, a new lesion appeared.
She died from 12 weeks after initiation of dabrafenib and trametinib treatment.
Conclusion.
To the best of our knowledge, this is the first report of BRAF mutation breast cancer treated with dabrafenib and trametinib and it heralds the possibility of targeted therapy for rare breast cancers.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Seo, Takuji& Noguchi, Emi& Yoshida, Masayuki& Mori, Taisuke& Tanioka, Maki& Sudo, Kazuki…[et al.]. 2020. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Reports in Oncological Medicine،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1149350
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Seo, Takuji…[et al.]. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Reports in Oncological Medicine No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1149350
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Seo, Takuji& Noguchi, Emi& Yoshida, Masayuki& Mori, Taisuke& Tanioka, Maki& Sudo, Kazuki…[et al.]. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Reports in Oncological Medicine. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1149350
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1149350
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر